Digest Network Come funziona
Network
/
Società
Ur
Non verificato

UroGen Pharma Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

42 comunicati stampa

Guarda tutti i comunicati
12/06/2025
Multimedialità
Igiene alimentare
Salute
Farmaceutica
Oncologia
Industria
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
06/06/2025
Mercato azionario
Finanza
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
02/06/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
02/06/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
27/05/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Fiere
Eventi
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
21/05/2025
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
12/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
01/05/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
27/04/2025
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0
27/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
Fonte
UroGen Pharma Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0